Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. Novo Nordisk A/S
  6. Summary
    NOVO B   DK0060534915

NOVO NORDISK A/S

(NOVO B)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Copenhagen
06/10/2021 06/11/2021 06/14/2021 06/15/2021 06/16/2021 Date
515.5(c) 516.8(c) 516.3(c) 519.5(c) 519.1(c) Last
2 189 401 1 622 173 1 600 347 1 564 053 1 647 456 Volume
+1.70% +0.25% -0.10% +0.62% -0.08% Change
More quotes
Financials
Sales 2021 133 B 21 521 M 21 521 M
Net income 2021 44 422 M 7 168 M 7 168 M
Net cash position 2021 4 605 M 743 M 743 M
P/E ratio 2021 27,0x
Yield 2021 1,86%
Sales 2022 144 B 23 299 M 23 299 M
Net income 2022 48 326 M 7 798 M 7 798 M
Net cash position 2022 10 485 M 1 692 M 1 692 M
P/E ratio 2022 24,1x
Yield 2022 2,04%
Capitalization 1 192 B 194 B 192 B
EV / Sales 2021 8,90x
EV / Sales 2022 8,18x
Nbr of Employees 45 157
Free-Float 69,8%
More Financials
Company
Novo Nordisk AS specializes in the design, production and marketing of pharmaceutical products. Net sales break down by family of products as follows: - products for treating diabetes and obesity (84.3%); - hemophilia treatment products (8.4%): mainly injections of protein; - growth hormones (6%): used for treatment of growth deficiencies in children; - hormone replacement products (1.3%): used for treatment of... 
Sector
Pharmaceuticals
Calendar
08/05 | 01:30amEarnings Release
More about the company
Ratings of Novo Nordisk A/S
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
A-
More Ratings
All news about NOVO NORDISK A/S
02:52pNOVO NORDISK A/Sá : Amalgam, Novo Nordisk to Launch Dose Check Insulin Titration..
MT
09:10aNOVO NORDISK A/Sá : Working With Lumen Bioscience to Evaluate Potential Strategi..
MT
06/15NOVO NORDISKá : Berenberg gives a Neutral rating
MD
06/14NOVO NORDISK A/Sá : Share repurchase programme (Form 6-K)
PU
06/10NOVO NORDISKá : Goldman Sachs keeps its Buy rating
MD
06/10NOVO NORDISKá : Bernstein gives a Buy rating
MD
06/10NOVO NORDISKá : JP Morgan keeps its Buy rating
MD
06/07NOVO NORDISK A/Sá : Share repurchase programme (Form 6-K)
PU
06/07NOVO NORDISKá : Goldman Sachs reiterates its Buy rating
MD
06/07NOVO NORDISK A/Sá : – Share repurchase programme
AQ
06/07NOVO NORDISK A/Sá : Wegovy™ (semaglutide 2.4 mg), the first and only once-..
PU
06/07NOVO NORDISK A/Sá : Risk of patient overlap between Wegovy and Saxenda obesity d..
RE
06/07NOVO NORDISK A/Sá : Risk of patient overlap between Wegovy and Saxenda obesity d..
RE
06/07NOVO NORDISK A/Sá : Weight Management Drug Gets US FDA Approval
MT
06/04NOVO NORDISK A/Sá : Gets FDA Nod for Weight Loss Drug Wegovy
MT
More news
News in other languages on NOVO NORDISK A/S
06/11MÄRKTE EUROPA/Gut behauptet - fallende Renditen stützen
06/07NOVO NORDISKá : rachat d'actions pour 3,3 milliards de DKK
05/31NOVO NORDISKá : a obtenu le 'Best Places to Work' au Koweït
05/31INNATE PHARMAá : Novo Nordisk sort du conseil de surveillance
05/17NOVO NORDISKá : rachat d'actions pour 3,3 milliards DKK
More news
Analyst Recommendations on NOVO NORDISK A/S
More recommendations
Stock Trading Strategies
NOVO NORDISK A/S - 2020
A good level to buy
BUY
More Stock Trading Analysis
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | MarketScreener
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 28
Average target price 472,56 DKK
Last Close Price 519,10 DKK
Spread / Highest target 7,88%
Spread / Average Target -8,97%
Spread / Lowest Target -34,5%
EPS Revisions
Managers and Directors
NameTitle
Lars Fruergaard J°rgensen President & Chief Executive Officer
Karsten Munk Knudsen Chief Financial Officer & Executive Vice President
Helge Lund Chairman
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Henrik Ehlers Wulff Executive VP & Head-Information Technology
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S21.76%194 583
JOHNSON & JOHNSON4.48%433 167
ROCHE HOLDING AG11.21%330 710
PFIZER, INC.6.76%221 613
NOVARTIS AG0.77%210 689
ABBVIE INC.7.82%204 582